Project Grant R01AI184534
Award Date 9/4/25
Completion Date 8/31/30
Dollars Obligated $811K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $6,319,992 to Tufts University School of Medicine to conduct research on how human papillomavirus (HPV) proteins reprogram host cell signaling pathways. The research aims to determine the essential cellular targets of the HPV E7 protein, specifically the RB1 and PTPN14 tumor suppressors, and how their inactivation enables HPV to drive...
- This $230,250 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the mechanisms by which the human papillomavirus (HPV) utilizes the early endosomal small GTPase Rab5 and its effector Rabankyrin-5 to form a complex that links the HPV-carrying endosome to the dynein motor protein, facilitating viral transport within the host cell. The...
- This Project Grant award of $533,707 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Tufts University School of Medicine to investigate how human papillomavirus (HPV) manipulates the Hippo signaling pathway to maintain persistent infection in basal epithelial cells. The research aims to elucidate the role of the HPV E7 protein in disrupting the balance between proliferation and...
- The University of Texas Health Science Center at Houston (UTHealth) received a $170,409 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports a study examining the prevalence of human papillomavirus (HPV) and HPV-related cancer prevention behaviors among people experiencing homelessness in the United States from 2006 to 2018. The study aims to establish a baseline understanding of HPV burden and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $244,328 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, which began on January 6, 2025 and will be completed by December 31, 2026, supports research on the impact of in utero HIV and antiretroviral exposure on the placenta and birth weight. The study will...
- This $2,920,356 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of norovirus capsid dynamics in enabling immune evasion. The project aims to leverage the highly tractable mouse norovirus system to elucidate the structural changes and host metabolite interactions that allow the virus to switch between antibody-recognized and...
- The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $660,205 Project Grant to The University of Texas Southwestern Medical Center to develop small molecule inhibitors targeting the bromodomain-containing protein 4 (BRD4) to block human papillomavirus (HPV) genome replication. The grant aims to identify and characterize compounds that can effectively inhibit the three stages of HPV DNA replication by targeting the phosphorylated...
- The University of Southern California (USC) received a $621,698 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to conduct research on the molecular analysis of mother-to-child transmission of Hepatitis B Virus (HBV). The goal of the research is to understand how HBV and its antigens in the mother affect the anti-HBV immunity of her children, which can lead to chronic...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,889 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas at Austin. The grant, awarded on November 12, 2024, aims to optimize the expression of short hairpin RNA (shRNA) in polyomavirus (PYV) genomes and conduct a proof-of-principle screen to assess how shRNA-armed PYVs can help unravel the mechanisms of PYV persistence and reactivation. This research is...
- This Project Grant award was provided by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program, to the University of Arizona. The $128,126 award, granted on December 1, 2024, supports research investigating how human papillomavirus (HPV) infection may evade the body's innate immune response by disrupting the cGAS/STING pathway, which is critical for antiviral and antitumor immunity. The project...